NuVasive interbody line gets green light for sagittal deformity treatment

The FDA has cleared NuVasive’s thoracolumbar interbody portfolio for the treatment of multilevel sagittal deformities.

Advertisement

The interbody line was previously approved for one- to two-level spine surgery, according to a Nov. 4 announcement from the spine device company.

The portfolio features the company’s Cohere, Modulus, TLX, MLX and CoRoent implants, which are available in several dimensions to fit each patient’s unique anatomy.

The implants can be integrated with NuVasive’s Bendini spinal rod bending system and its surgical planning tools designed for improved sagittal alignment.

More articles on devices:
Robotics in spine surgery: 17 notes for surgeons, ASCs & administrators
Zimmer Biomet net sales increase 2%, knee sales dip .5% in Q3
10 most influential orthopedic specialists on Twitter in Q3, according to GlobalData

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.